A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study is investigating a new medication called imlunestrant for premenopausal women with early breast cancer that's sensitive to hormones (Estrogen Receptor-positive, HER2-negative). The study has two main groups, called cohorts. Cohort 1 aims to understand how imlunestrant affects cancer cells. Some women will take imlunestrant with treatment to stop their ovaries working, and some without. This will be compared to tamoxifen, another common breast cancer drug. The treatment for this group lasts up to 29 days. Cohort 2 focuses on how imlunestrant affects the ovaries when taken without ovarian suppression. Again, this will be compared to tamoxifen. This group's treatment will last up to 6 months. Both groups involve women who can still have periods. The overall goal is to see if imlunestrant could be a future treatment option for this type of breast cancer.
एक नजर में
यह अध्ययन किस बारे में है?
This research study is about a new medicine called imlunestrant (also known by its code LY3484356), which is being tested for a specific type of early breast cancer. This particular type of breast cancer is called "estrogen receptor-positive" and "HER2-negative." This means the cancer cells grow because of the hormone oestrogen, and they don't have too much of a protein called HER2. This is a common type of breast cancer, and the study is focused on women who are still having periods (premenopausal).
The study is divided into two main parts, called cohorts, each looking at slightly different things. Cohort 1 will help doctors learn how imlunestrant directly affects cancer cells. They will compare it to an existing treatment called tamoxifen. Some women will also receive treatment to suppress their ovaries, while others won't, to see how that affects the new medicine's impact. Cohort 2 will specifically look at how imlunestrant affects the ovaries themselves when ovarian function isn't suppressed, again comparing it to tamoxifen.
The overall aim is to understand if imlunestrant could be a new and effective treatment option for premenopausal women with this type of early breast cancer. By comparing it to tamoxifen, which is a standard treatment, researchers can see if it works similarly or even better. This kind of research is important for finding new ways to help people with cancer.
मुख्य निष्कर्ष
- Study is for premenopausal women with specific type of early breast cancer.
- Investigates a new drug, imlunestrant, compared to tamoxifen.
- Aims to understand drug's effect on cancer cells and ovaries.
- Treatment duration varies from less than a month to up to six months.
- Participation involves taking study medication and regular medical check-ups.
- आप किसी भी समय अध्ययन से हट सकते हैं।.
कौन पात्र हो सकता है?
This study is specifically looking for premenopausal women (meaning you still have periods) who have been diagnosed with a certain type of early breast cancer. This must be breast cancer that is sensitive to oestrogen (ER-positive) and doesn't have too much of the HER2 protein (HER2-negative). You should generally feel well and be able to swallow tablets or capsules.
For Cohort 1, your breast cancer should be in stages I to III and show a certain level of cell growth (Ki-67 at least 10%). You'd also need to be willing to provide tissue samples from your tumour before and during treatment. For Cohort 2, you should have already had surgery for your ER+, HER2- early breast cancer and received at least 4.5 years of hormone therapy, or at least 2 years with no further ovarian suppression planned.
There are also some reasons why you might not be able to join. For example, if you have inflammatory breast cancer, other serious medical conditions, or have recently had major surgery. You also can't have had certain other cancers unless they've been gone for a long time without treatment. If you could become pregnant, you would need to use effective non-hormonal contraception during the study.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- Am I a premenopausal woman (do I still have periods)?
- Do I have ER-positive, HER2-negative early breast cancer?
- Do I generally feel well and am I able to swallow tablets?
- Have I had surgery for my breast cancer (for Cohort 2)?
- Am I using effective non-hormonal contraception if I could become pregnant?
भागीदारी में क्या शामिल है?
If you decide to take part in this study, what happens next depends on which group (cohort) you would be in. For Cohort 1, the treatment period will be quite short, lasting up to 29 days. For Cohort 2, the treatment might last longer, up to 6 months. During this time, you would take either the new medicine, imlunestrant, or an existing one, tamoxifen, depending on which group you're assigned to. Some participants might also receive a treatment to suppress their ovarian function.
You would have regular appointments and tests so the doctors can monitor how the treatment is affecting you and your cancer. This could include providing tumour samples (for Cohort 1), blood tests, and scans. The team will explain exactly what's involved in your specific case, including how often you'd need to visit the clinic and any follow-up appointments after the main treatment period ends. All the details will be discussed with you before you make any decisions.
संभावित जोखिम और लाभ
Locations (60)
- बर्मिंघम में अलबामा विश्वविद्यालयसत्यापित पोस्टकोडबर्मिंघम, संयुक्त राज्य अमेरिका
- Ironwood Cancer & Research Centersसत्यापित पोस्टकोडचैंडलर, संयुक्त राज्य अमेरिका
- USC/Norris Comprehensive Cancer Centerसत्यापित पोस्टकोडलॉस एंजेलेस, संयुक्त राज्य अमेरिका
- UCLA Hematology/Oncology - Parksideसत्यापित पोस्टकोडसांता मोनिका, संयुक्त राज्य अमेरिका
- Banner MD Anderson Cancer Center at North Colorado Medical Centerसत्यापित पोस्टकोडGreeley, United States
- Banner MD Anderson Cancer Center at McKee Medical Centerसत्यापित पोस्टकोडLoveland, United States
- AdventHealth Altamonte Springsसत्यापित पोस्टकोडAltamonte Springs, United States
- विनशिप कैंसर संस्थानसत्यापित पोस्टकोडअटलांटा, संयुक्त राज्य अमेरिका
- Indiana University Melvin and Bren Simon Cancer Centerसत्यापित पोस्टकोडइंडियानापोलिस, संयुक्त राज्य अमेरिका
- मैसाचुसेट्स जनरल अस्पतालसत्यापित पोस्टकोडबोस्टन, संयुक्त राज्य अमेरिका
- डाना-फार्बर कैंसर संस्थानसत्यापित पोस्टकोडबोस्टन, संयुक्त राज्य अमेरिका
- वॉशिंगटन यूनिवर्सिटी स्कूल ऑफ मेडिसिनसत्यापित पोस्टकोडसेंट लुइस, संयुक्त राज्य अमेरिका
सामान्य प्रश्न
यह अध्ययन किस प्रकार के स्तन कैंसर के लिए है?
This study is for premenopausal women with early-stage breast cancer that is Estrogen Receptor-positive (ER+) and HER2-negative (HER2-). This means your cancer grows because of oestrogen.
What is imlunestrant?
Imlunestrant is a new medicine being tested. Researchers want to see how it affects breast cancer cells and the ovaries, comparing it to an existing drug called tamoxifen.
मुझे उपचार पर कितने समय तक रहना होगा?
For one group (Cohort 1), treatment lasts up to 29 days. For the other group (Cohort 2), treatment can last up to 6 months.
Will I have to take other medications?
Depending on the group, you might also take a treatment to suppress your ovarian function, or you might be taking tamoxifen instead of imlunestrant.
Can I still take part if I've had breast cancer before?
Usually no, if it was an invasive or inflammatory type. However, some very early or non-melanoma skin cancers are usually allowed if they have been treated and are gone for a long time.
और अधिक जानने के लिए कैसे पता करें
परीक्षण प्रश्न या भागीदारी प्रश्न: 1-877-CTLILLY (1-877-285-4559) या
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
भाग लेने में रुचि रखते हैं?
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.